Advances in antiretroviral and anti-hepatitis C virus infection therapy: A report from CROI 2012 - March 5-8, Seattle, Oregon, USA

Research output: Contribution to journalArticle

Abstract

The Conference on Retroviruses and Opportunistic Infections (CROI) remains a venue for important exchanges of information and dissemination of knowledge. New anti-hepatitis C virus (HCV) therapies remain a focus of interest at CROI 2012. Telaprevir and boceprevir, two recently approved, direct-acting anti-HCV drugs, have now been associated with improved virological responses in patients co-infected with HIV and hepatitis C. However, overlapping toxicities and substantial drug-drug interactions will severely limit their clinical utility. Yet another single-pill, once-daily antiretroviral regimen is on the horizon, and the proof of concept for purging HIV from latent CD4+ cells may have been provided at CROI 2012.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalDrugs of the Future
Volume37
Issue number5
DOIs
StatePublished - 2012

Fingerprint

Retroviridae Infections
Opportunistic Infections
Virus Diseases
Hepacivirus
HIV
Information Dissemination
Hepatitis C
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Therapeutics
Pharmaceutical Preparations

Keywords

  • Boceprevir
  • Dolutegravir
  • Elvitegravir
  • Hepatitis
  • HIV
  • Telaprevir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{4b41fdec88c3476db18f720449bd4144,
title = "Advances in antiretroviral and anti-hepatitis C virus infection therapy: A report from CROI 2012 - March 5-8, Seattle, Oregon, USA",
abstract = "The Conference on Retroviruses and Opportunistic Infections (CROI) remains a venue for important exchanges of information and dissemination of knowledge. New anti-hepatitis C virus (HCV) therapies remain a focus of interest at CROI 2012. Telaprevir and boceprevir, two recently approved, direct-acting anti-HCV drugs, have now been associated with improved virological responses in patients co-infected with HIV and hepatitis C. However, overlapping toxicities and substantial drug-drug interactions will severely limit their clinical utility. Yet another single-pill, once-daily antiretroviral regimen is on the horizon, and the proof of concept for purging HIV from latent CD4+ cells may have been provided at CROI 2012.",
keywords = "Boceprevir, Dolutegravir, Elvitegravir, Hepatitis, HIV, Telaprevir",
author = "Zelalem Temesgen",
year = "2012",
doi = "10.1358/dof.2012.037.05.1799889",
language = "English (US)",
volume = "37",
pages = "369--374",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Advances in antiretroviral and anti-hepatitis C virus infection therapy

T2 - A report from CROI 2012 - March 5-8, Seattle, Oregon, USA

AU - Temesgen, Zelalem

PY - 2012

Y1 - 2012

N2 - The Conference on Retroviruses and Opportunistic Infections (CROI) remains a venue for important exchanges of information and dissemination of knowledge. New anti-hepatitis C virus (HCV) therapies remain a focus of interest at CROI 2012. Telaprevir and boceprevir, two recently approved, direct-acting anti-HCV drugs, have now been associated with improved virological responses in patients co-infected with HIV and hepatitis C. However, overlapping toxicities and substantial drug-drug interactions will severely limit their clinical utility. Yet another single-pill, once-daily antiretroviral regimen is on the horizon, and the proof of concept for purging HIV from latent CD4+ cells may have been provided at CROI 2012.

AB - The Conference on Retroviruses and Opportunistic Infections (CROI) remains a venue for important exchanges of information and dissemination of knowledge. New anti-hepatitis C virus (HCV) therapies remain a focus of interest at CROI 2012. Telaprevir and boceprevir, two recently approved, direct-acting anti-HCV drugs, have now been associated with improved virological responses in patients co-infected with HIV and hepatitis C. However, overlapping toxicities and substantial drug-drug interactions will severely limit their clinical utility. Yet another single-pill, once-daily antiretroviral regimen is on the horizon, and the proof of concept for purging HIV from latent CD4+ cells may have been provided at CROI 2012.

KW - Boceprevir

KW - Dolutegravir

KW - Elvitegravir

KW - Hepatitis

KW - HIV

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84952979942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952979942&partnerID=8YFLogxK

U2 - 10.1358/dof.2012.037.05.1799889

DO - 10.1358/dof.2012.037.05.1799889

M3 - Article

AN - SCOPUS:84952979942

VL - 37

SP - 369

EP - 374

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 5

ER -